Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soliqua 100/33 vs Lantus in diverse T2DM patients
NCT03434119Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Feb 2018; status: terminated.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03434119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03434119.